What question did this study set out to answer?

To compare the subcutaneous absorption rates of insulin glargine with NPH insulin and evaluate the influence of different injection sites.

June 1, 2000Diabetes CareOpen Access

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

View Full Paper

Ask AI

Bookmark

Why the study?

Does insulin glargine have a delayed subcutaneous absorption rate compared to NPH insulin in healthy men?

Population

24 healthy men (12 in study 1, 12 in study 2), aged 18-50 years.

Comparison

125I-labeled insulin glargine administered… vs NPH insulin and placebo; comparison between…

Design

RCT, randomized crossover design

Follow-up

24 hours

Authors

DODavid R. OwensSwansea University PCPhilip A. CoatesStafford College SLStephen D. LuzioSwansea University

Discussion

Member takes

Implication

Supports glargine as peakless basal insulin; extends site-independent absorption data in healthy volunteers.

Key Points

To compare the subcutaneous absorption rates of insulin glargine with NPH insulin and evaluate the influence of different injection sites.
Conducted 2 studies with a randomized crossover design involving 12 healthy men aged 18-50 years.
In study 1, participants received 0.15 U/kg of three formulations of insulin glargine and NPH insulin through abdominal injections.
In study 2, 0.2 U/kg of insulin glargine was injected into the arm, leg, and abdominal regions.
NPH insulin showed significantly faster absorption (T75% 3.2 h) compared to insulin glargine (T75% 8.8 and 11.0 h, P < 0.0001).
Residual radioactivity at 24 h for NPH insulin was significantly lower at 21.9%, compared to insulin glargine (43.8% and 52.2%, P < 0.0001).
No significant absorption rate differences were observed for insulin glargine across the three injection sites (T75% ranged from 11.9 to 15.3 h).

Structured PICO

Does insulin glargine have a delayed subcutaneous absorption rate compared to NPH insulin in healthy men?

Population

24 healthy men (12 in study 1, 12 in study 2), aged 18-50 years.

Intervention

125I-labeled insulin glargine (15, 30, and 80 microg/ml zinc) administered subcutaneously (0.15 U/kg or 0.2 U/kg).

Comparator

NPH insulin and placebo (Study 1); comparison between injection sites (arm, leg, abdomen) (Study 2).

Outcome

Subcutaneous absorption rates (T75% - time for 25% of administered radioactivity to disappear) and appearance in plasma.surrogate

Insulin glargine exhibits a significantly delayed subcutaneous absorption compared to NPH insulin, with no distinct peak and consistent absorption across different injection sites.

Cite This Study

Owens et al. (2000) studied this question.

synapsesocial.com/papers/6a75fdfc82bd1ced277866b3 https://doi.org/10.2337/diacare.23.6.813

View Full Paper

Ask AI

Bookmark